Instil Bio (TIL)
Biotechnology developer seeking therapeutic candidates through acquisitions and in-licensing.
Something off on this page? Send us feedback.
Seeks to acquire or in-license therapeutic candidates for further development across diseases with unmet need. The single-segment biotechnology business has no candidate in active development and no product-sales revenue, while a former California manufacturing site generates noncore rental income.
Pursues external innovation through acquisitions, in-licensing, and related transactions. The goal is to source novel therapeutic candidates across several therapeutic areas and advance them through preclinical research, clinical trials, regulatory review, and, if approved, commercialization.
A California manufacturing facility leased to AstraZeneca provides noncore rental income; headquarters are in Dallas, with laboratory and office space in the UK. This single operating segment has no product candidate in active development and has never generated product-sales revenue. Any acquired program would depend on licensed intellectual property, third-party manufacturing, successful clinical testing, capital access, and approvals from the FDA or foreign regulators.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Piper Sandler | Initiate | Overweight | |||
| Jan 7, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Jan 7, 2026 | H.C. Wainwright | Downgrade | Buy | Neutral | ||
| Jan 6, 2026 | Robert W. Baird | Target | $180 | $7 | ||
| Jan 6, 2026 | Baird | Downgrade | Outperform | Neutral |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $69.7M · Total debt $3.7M · Total assets $197.7M · Shareholders' equity $107.4M
- Revenue
- $0
- Operating income
- −$5.6M
- Net income
- −$4.3M
No dividends on record.
| Institutions31 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 33.88% | 2.30M shares | |
| Otherremainder | ≈ 66.12% | 4.48M shares |
6.78M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
BML Capital Management, LLCInstitution | 9.52% | 645,600 | 13Fas of Mar 31, 2026 |
BML Investment Partners, L.P.Institution | 9.52% | 645,600 | 13Gfiled Feb 9, 2026 ↗ |
CPMG IncInstitution | 6.06% | 410,922 | 13Fas of Mar 31, 2026 |
Vivo Capital, LLCInstitution | 4.32% | 292,743 | 13Fas of Mar 31, 2026 |
Kalehua Capital Management LLCInstitution | 2.70% | 183,030 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 10, 2025 | Sandeep Laumas | officer: CFO and CBO | −30,000 | $23.39 |
Not reported.